This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.theguardian.com/business/2016/sep/20/glaxosmithkline-names-emma-walmsley-new-ceo-gsk
The article has changed 10 times. There is an RSS feed of changes available.
| Version 2 | Version 3 |
|---|---|
| GSK makes Emma Walmsley most powerful woman in FTSE 100 | GSK makes Emma Walmsley most powerful woman in FTSE 100 |
| (35 minutes later) | |
| GlaxoSmithKline has appointed Emma Walmsley as chief executive, making her the most powerful woman in the FTSE 100. | GlaxoSmithKline has appointed Emma Walmsley as chief executive, making her the most powerful woman in the FTSE 100. |
| Britain’s biggest drugs company said Walmsley would take over from Sir Andrew Witty when he retires in March. Walmsley joined GSK in 2010 and runs its consumer healthcare division. | Britain’s biggest drugs company said Walmsley would take over from Sir Andrew Witty when he retires in March. Walmsley joined GSK in 2010 and runs its consumer healthcare division. |
| Walmsley will be one of just six female chief executives in the FTSE 100. EasyJet, Imperial Brands, Whitbread, Royal Mail and Kingfisher are also run by women. | Walmsley will be one of just six female chief executives in the FTSE 100. EasyJet, Imperial Brands, Whitbread, Royal Mail and Kingfisher are also run by women. |
| GSK, with a market value of £80bn, is more than twice as big as the next largest female-led company, the tobacco company Imperial Brands, which is valued at £37bn. | GSK, with a market value of £80bn, is more than twice as big as the next largest female-led company, the tobacco company Imperial Brands, which is valued at £37bn. |
| Sir Philip Hampton, GSK’s chairman, is leading a government-commissioned review into increasing the number of women senior executives at Britain’s top companies. Part of the plan is to get more women into senior management positions who can go on to lead Britain’s biggest companies. | Sir Philip Hampton, GSK’s chairman, is leading a government-commissioned review into increasing the number of women senior executives at Britain’s top companies. Part of the plan is to get more women into senior management positions who can go on to lead Britain’s biggest companies. |
| Hampton said: “Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare.” | Hampton said: “Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare.” |
| Walmsley has been a member of GSK’s top executive team since 2011. Before joining GSK she was at L’Oréal, the French cosmetics company, for 17 years and has worked in the UK, Europe, China and the US. | |
| Today we’ve announced Emma Walmsley will succeed Sir Andrew Witty as CEO of GSK. Read more: https://t.co/amyuIRK1uJ pic.twitter.com/Z7awbyPKt3 | Today we’ve announced Emma Walmsley will succeed Sir Andrew Witty as CEO of GSK. Read more: https://t.co/amyuIRK1uJ pic.twitter.com/Z7awbyPKt3 |
| Walmsley said: “I am delighted and honoured to be appointed GSK’s next CEO. I’m looking forward to working with Andrew and other leaders over the next few months to ensure a smooth handover and to develop plans for 2017 and beyond.” | Walmsley said: “I am delighted and honoured to be appointed GSK’s next CEO. I’m looking forward to working with Andrew and other leaders over the next few months to ensure a smooth handover and to develop plans for 2017 and beyond.” |
| GSK has been looking for a new chief executive since Whitty announced his retirement in March 2016. He had been under pressure to speed up turnaround plans for GSK following several years of weak financial performance. | GSK has been looking for a new chief executive since Whitty announced his retirement in March 2016. He had been under pressure to speed up turnaround plans for GSK following several years of weak financial performance. |
| Witty was behind the three-part, £15bn deal with Swiss rival Novartis in 2014 to pool consumer healthcare assets and exchange oncology and vaccine businesses, which was seen as an innovative move in the industry. Walmsley headed the enlarged consumer division. | Witty was behind the three-part, £15bn deal with Swiss rival Novartis in 2014 to pool consumer healthcare assets and exchange oncology and vaccine businesses, which was seen as an innovative move in the industry. Walmsley headed the enlarged consumer division. |